Romiplostim治疗化疗引起的血小板减少症：一项对儿童实体瘤患者安全性、有效性和未来研究的病例队列评估。

IF 2.3 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-09-03 DOI:10.1002/pbc.32011

Lev Gorfinkel, Emily M. Harris, Catherine B. Wall, Allison F. O'Neill

{"title":"Romiplostim治疗化疗引起的血小板减少症：一项对儿童实体瘤患者安全性、有效性和未来研究的病例队列评估。","authors":"Lev Gorfinkel, Emily M. Harris, Catherine B. Wall, Allison F. O'Neill","doi":"10.1002/pbc.32011","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Romiplostim for chemotherapy-induced thrombocytopenia (CIT) is not well-studied in children. This single-center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays (<i>p</i> = 0.42) or dose reductions (<i>p</i> > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.</p>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 11","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Romiplostim for Chemotherapy-Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors\",\"authors\":\"Lev Gorfinkel, Emily M. Harris, Catherine B. Wall, Allison F. O'Neill\",\"doi\":\"10.1002/pbc.32011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Romiplostim for chemotherapy-induced thrombocytopenia (CIT) is not well-studied in children. This single-center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays (<i>p</i> = 0.42) or dose reductions (<i>p</i> > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.</p>\\n </div>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\"72 11\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.32011\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.32011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Romiplostim治疗化疗引起的血小板减少症（CIT）在儿童中的研究还不充分。这项单中心回顾性队列研究描述了24例儿童实体瘤患者，他们开始使用romiplostim，化疗中位时间为5个月（范围：0-14个月），最大中位剂量为6.5µg/kg（范围：1-10）。少数患者的周期延迟减少（30%）或剂量减少（13%）。未接受罗米普罗stim的比较队列在周期延迟（p = 0.42）或剂量减少（p = 0.99）方面没有差异。没有不良事件发生。Romiplostim对儿童实体瘤是安全的，但需要进一步的前瞻性疗效研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Romiplostim for Chemotherapy-Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors

查看原文本刊更多论文

Romiplostim for Chemotherapy-Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors

Romiplostim for chemotherapy-induced thrombocytopenia (CIT) is not well-studied in children. This single-center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays (p = 0.42) or dose reductions (p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.